

## Curriculum Vitae

### Personal information

Surname(s) / First name(s) **Casali, Paolo Giovanni**

Nationality Italian

Date of birth 28 December 1958

Gender Male

### Work experience

Dates From 1 November 2016 to present

Occupation or position held **Director, Medical Oncology Unit 2**

Main activities and responsibilities Chairing a medical oncology unit devoted to adult patients with sarcoma and coordination of the Italian Rare Cancer Network

Name and address of employer **Fondaz. IRCCS "Istituto Nazionale dei Tumori"**, via G. Venezian 1, 20133 **Milano**, Italy

Type of business or sector Medical oncology

Dates From 1 November 2016 to present

Occupation or position held **Associate Professor of Medical Oncology**

Main activities and responsibilities Education and Research, Medical School

Name and address of employer **University of Milano**, Italy

Type of business or sector University

Dates From December 2014 to October 2016

Occupation or position held Director (ad interim), Medical Oncology Unit 2

Main activities and responsibilities Chairing a new medical oncology unit devoted to adult patients with sarcoma and coordination of the Italian Rare Cancer Network

Name and address of employer Fondaz. IRCCS "Istituto Nazionale dei Tumori", via G. Venezian 1, 20133 Milano, Italy

Type of business or sector Medical oncology

Dates From June 2011 to November 2014

Occupation or position held Head, Adult Mesenchymal Tumour Medical Oncology Unit

Main activities and responsibilities Coordinating a departmental medical oncology unit devoted to adult patients with sarcoma

Name and address of employer Fondaz. IRCCS "Istituto Nazionale dei Tumori", via G. Venezian 1, 20133 Milano, Italy

Type of business or sector Medical oncology

Dates From April 2004 to May 2011

Occupation or position held Head, Adult Sarcoma Medical Treatment Unit

Main activities and responsibilities Coordinating a medical oncology unit devoted to adult patients with sarcoma

Name and address of employer Fondaz. IRCCS "Istituto Nazionale dei Tumori", via G. Venezian 1, 20133 Milano, Italy

Type of business or sector Medical oncology

Dates	From March 1994 to March 2004
Occupation or position held	Assistant physician
Main activities and responsibilities	Full staff position as Medical oncologist (with functional responsibility for adult sarcoma medical oncology from January 2002)
Name and address of employer	Istituto Nazionale Tumori, via G. Venezian 1, 20133 Milano, Italy
Type of business or sector	Health care: medical oncology

Dates	From October 1985 to February 1994
Occupation or position held	Clinical fellow / Associate Physician
Main activities and responsibilities	Non full staff positions as Medical oncologist
Name and address of employer	Istituto Nazionale Tumori, via G. Venezian 1, 20133 Milano, Italy
Type of business or sector	Health care: medical oncology

Dates	From 2003 to 2016
Occupation or position held	Adjunct Professor
Main activities and responsibilities	Teaching Medical oncology of rare cancers to postgraduate students of Oncology
Name and address of employer	Postgraduate School of Medical Oncology, Medical School, University, Milan, Italy
Type of business or sector	University

Dates	From 1999 to 2003
Occupation or position held	Tutor
Main activities and responsibilities	Tutoring postgraduate students of Oncology
Name and address of employer	Postgraduate School of Oncology, University, Milan, Italy
Type of business or sector	University

## Education and training

Dates	2015
Title of qualification awarded	<b>Certificate of Management for Medical Unit Directors</b>
Principal subjects/occupational skills covered	Health management, Direction of hospital medical units
Name and type of organisation providing education and training	Eupolis Lombardia – School of Health Management, Milano

Dates	1994
Title of qualification awarded	<b>European Certification on Medical Oncology</b>
Principal subjects/occupational skills covered	Medical oncology
Name and type of organisation providing education and training	European Society for Medical Oncology (ESMO)

Dates	From 1987 to 1990
Title of qualification awarded	<b>Postgraduate certificate in Clinical Oncology</b>
Principal subjects/occupational skills covered	Clinical oncology
Name and type of organisation providing education and training	University, Parma, Italy
Level in national or international classification	ISCED 5A (Field of Education: 72)

Dates From 1984 to 1987  
 Title of qualification awarded **Postgraduate certificate in Haematology**  
 Principal subjects/occupational skills covered Haematology  
 Name and type of organisation providing education and training University, Milano, Italy  
 Level in national or international classification ISCED 5A (Field of Education: 72)

Dates 1984  
 Title of qualification awarded **Italian Medical Licence**  
 Principal subjects/occupational skills covered Medicine  
 Name and type of organisation providing education and training University, Milano, Italy

Dates From 1977 to 1984  
 Title of qualification awarded **Medical Degree** (cum laude)  
 Principal subjects/occupational skills covered Medicine  
 Name and type of organisation providing education and training University, Milano, Italy  
 Level in national or international classification ISCED 5A (Field of Education: 72)

**Personal skills and competences**

Mother tongue(s) **Italian**

Other language(s)

Self-assessment

*European level (\*)*

**English**

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user

(\*) *Common European Framework of Reference for Languages*

## Additional information

- Secretary of the Ethics Committee of Istituto Nazionale Tumori, Milano, Italy, from 2005 to present
- Member of the Executive Board (from 2019 also of the Council) of the *European Society for Medical Oncology* (ESMO), from 2005 to 2010 as Treasurer, from 2011 to 2015 as Chair of the Public Policy Committee, from 2016 to 2018 as Chair of the Public Policy steering committee and the EU Policy Committee, currently as Director of the Public Policy Division and Chair of the European Policy Committee
- Sarcoma Faculty member (coordinator from 2006 to 2011) of the *European Society for Medical Oncology* (ESMO)
- Member of the Board of Directors of the *European CanCer Organization* (ECCO) from 2014 to 2015
- Member of the Board of Directors of the *Connective Tissue Oncology Society* (CTOS), from 2017 to 2019.
- Coordinator of the Steering committee of *Rare Cancers Europe*
- Coordinator of the *Joint Action on Rare Cancers* (JARC) of the European Union, carried out from 2017 to 2019 within the framework of the Third Health Programme of the European Union (EU)
- Coordinator of the Sarcoma domain of the *European Reference Network for Adult Rare Solid Cancers* (EURACAN)
- Founder and coordinator of the *Italian Network on Rare Cancers* (currently the professional network pertaining to the new *Italian National Network on Rare Cancers*), from 1997 to present
- Member of the Coordination group of the *Italian National Network on Rare Cancers*, from 2018 to present
- Coordinator of the Rare Tumours programme of the *European School of Oncology* (ESO)
- Secretary of the *Italian Sarcoma Group* (ISG)
- Member of the *EORTC Soft Tissue and Bone Sarcoma Group*
- Member from 2006 to 2009 (and Track leader in 2009) of the Cancer Education Committee of the *American Society of Clinical Oncology* (ASCO)
- Member of the Steering committee of the *Clinical Academic Cancer Research Forum* (CAREFOR)
- Member of the Board of the *Federation of Italian Cooperative Oncology Groups* (FICOG), on behalf of the Italian Sarcoma Group
- Editor in chief of *Clinical Sarcoma Research*
- Member of the Editorial Board of *Annals of Oncology*
- Member of the following professional/scientific societies:
  - *European Society for Medical Oncology* (ESMO)
  - *Italian Association of Medical Oncology* (AIOM)
  - *American Society of Clinical Oncology* (ASCO)
  - *Connective Tissue Oncology Society* (CTOS)
  - *Society for Medical Decision Making* (SMDM)

**Publications:** see Annexes 1-2-3

## Annexes

Annex 1: List of **Medline-indexed scientific publications, in English**

Annex 2: List of **Book chapters, in English**

Annex 3: List of **Books, in Italian**

## Annex 1

### List of Medline-indexed scientific publications, in English

**h-index:** 72  
**No. of citations:** 19,729  
**IF (as from 2005):** 1,655

1. Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, **Casali PG**, Woll PJ, Gronchi A; EORTC – Soft Tissue and Bone Sarcoma Group. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. **Eur J Cancer**. 2019 Mar;109:51-60.
2. Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, **Casali PG**, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. **Lancet Oncol**. 2019 Jan;20(1):134-144.
3. Nizri E, Fiore M, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Morosi C, Stacchiotti S, **Casali PG**, Gronchi A. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients-A propensity score analysis. **J Surg Oncol**. 2019 Mar;119(3):318-323.
4. Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, Gronchi A, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, **Casali PG**. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. **Eur J Cancer**. 2019 Jan;106:225-233.
5. Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, **Casali PG**, Sanfilippo R. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. **Oncologist**. 2018 Dec 5. pii: theoncologist.2018-0338. [Epub ahead of print]
6. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pèchoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, **Casali PG**, Wunder JS, Gronchi A. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. **Eur J Cancer**. 2018 Dec;105:19-27.
7. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, **Casali PG**, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators. Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic Malignancies (TYME). **Cancer Treat Rev**. 2018 Dec;71:76-87.
8. **Casali PG**, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2018 Oct 1;29(Supplement\_4):iv79-iv95.
9. **Casali PG**, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2018 Oct 1;29(Supplement\_4):iv268-iv269.
10. Stacchiotti S, Morosi C, Lo Vullo S, Casale A, Palassini E, Frezza AM, Dinoi G, Messina A, Gronchi A, Cavalleri A, Venturelli E, Morelli D, Pilotti S, Collini P, Brich S, Tamborini E, Mariani L, **Casali PG**. Imatinib and

everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. **Cancer**. 2018 Oct 15;124(20):4056-4063.

11. **Casali PG**, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2018 Oct 1;29(Supplement\_4):iv267.
12. Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, **Casali PG**, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. **Ther Adv Med Oncol**. 2018 Aug 29;10:1758835918794623.
13. Stiller CA, Botta L, Brewster DH, Ho VKY, Frezza AM, Whelan J, **Casali PG**, Trama A, Gatta G; EUROCORE-5 Working Group. Survival of adults with cancers of bone or soft tissue in Europe-Report from the EUROCORE-5 study. **Cancer Epidemiol**. 2018 Oct;56:146-153.
14. Frezza AM, Lee ATJ, Nizri E, Sbaraglia M, Jones RL, Gronchi A, Dei Tos AP, **Casali PG**. 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. **ESMO Open**. 2018 Jun 28;3(4):e000390.
15. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada GP, Colombo C, Gronchi A, Pession A, **Casali PG**, Stacchiotti S, Pantaleo MA. Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. **Int J Mol Sci**. 2018 Jun 23;19(7).
16. Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, **Casali PG**, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. **JAMA Oncol**. 2018 Sep 1;4(9):e180219. Epub 2018 Sep 13.
17. Frezza AM, Trama A, Blay JY, **Casali PG**. Networking in rare cancers: What was done, what's next. **Eur J Surg Oncol**. 2019 Jan;45(1):16-18.
18. Raimondi A, Colombo F, Pintarelli G, Morosi C, Renne SL, Frezza AM, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, **Casali PG**, Stacchiotti S. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review. **Anticancer Drugs**. 2018 Jul;29(6):589-595.
19. Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, **Casali PG**, Picci P, Gronchi A. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. **Eur J Cancer**. 2018 Feb 20;93:28-36.
20. Fiore M, Ford S, Callegaro D, Sangalli C, Colombo C, Radaelli S, Frezza AM, Renne SL, **Casali PG**, Gronchi A. Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard? **Ann Surg Oncol**. 2018 Feb 22. [Epub ahead of print]
21. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, **Casali PG**, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A. Global cancer control: responding to the growing burden, rising costs and inequalities in access. **ESMO Open**. 2018 Feb 2;3(2):e000285.
22. Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, **Casali PG**, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. **Ther Adv Med Oncol**. 2017 Dec;9(12):731-739.
23. Provenzano S, Raimondi A, Bertulli RM, Colia V, Renne SL, Collini P, Dagrada G, Callegaro D, Fiore M, Greco FG, **Casali PG**. Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor. **Clin Sarcoma Res**. 2017 Dec 28;7:20.
24. De Sanctis R, Giordano L, Colombo C, De Paoli A, Navarria P, Sangalli C, Buonadonna A, Sanfilippo R, Bertola G, Fiore M, Marrari A, Navarria F, Bertuzzi A, **Casali PG**, Basso S, Santoro A, Quagliuolo V, Gronchi A. Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the

- Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STs) Protocol 0303. **Ann Surg Oncol.** 2017 Dec;24(13):3872-3879.
25. Pasquali S, Bonvalot S, Tzanis D, **Casali PG**, Trama A, Gronchi A; RARECARENet Working Group. Treatment challenges in and outside a network setting: Soft tissue sarcomas. **Eur J Surg Oncol.** 2017 Sep 19. [Epub ahead of print]
  26. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, **Casali PG**, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. **Oncotarget.** 2017 May 17;8(36):60036-60045.
  27. Colia V, Fumagalli E, Provenzano S, Bertulli R, Stacchiotti S, Morosi C, Collini P, Gronchi A, **Casali PG**, Sanfilippo R. High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. **Sarcoma.** 2017;2017:3739159. Epub 2017 Aug 30.
  28. Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Tos APD, Barisella M, Gronchi A, **Casali PG**, Sanfilippo R. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. **Clin Sarcoma Res.** 2017 Aug 22;7:16.
  29. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, **Casali PG**, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. **ESMO Open.** 2017 Jan 16;1(6):e000142.
  30. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, **Casali PG**, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. **Oncologist.** 2017 Jul 28. [Epub ahead of print]
  31. Corino VDA, Montin E, Messina A, **Casali PG**, Gronchi A, Marchianò A, Mainardi LT. Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions. **J Magn Reson Imaging.** 2017 Jun 27. [Epub ahead of print]
  32. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, **Casali PG**. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STs 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. **Lancet Oncol.** 2017 Jun;18(6):812-822
  33. Pasquali S, Palassini E, Stacchiotti S, **Casali PG**, Gronchi A. Neoadjuvant treatment: a novel standard? **Curr Opin Oncol.** 2017 Jul;29(4):253-259
  34. Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, Stacchiotti S, **Casali PG**, Gronchi A. Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. **Cancer J.** 2017 Mar/Apr;23(2):86-91.
  35. MacNeill AJ, Gronchi A, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, **Casali PG**, Pollock RE, Barretta F, Raut CP, Strauss DC. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group. **Ann Surg.** 2017 Apr 7. [Epub ahead of print]
  36. Urbini M, Astolfi A, Pantaleo MA, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, Gronchi A, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession A, Biasco G, **Casali PG**, Stacchiotti S. HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma. **Genes Chromosomes Cancer.** 2017 Jul;56(7):582-586.
  37. **Casali PG**, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. **J Clin Oncol.** 2017 May 20;35(15):1713-1720.
  38. Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, **Casali PG**, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. **Eur J Cancer.** 2017 May;76:84-92.
  39. Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, D'Ambrosio L, Stacchiotti S, **Casali PG**, Picci P. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. **Clin Sarcoma Res.** 2017 Feb 28;7:4.

40. Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp C, **Casali PG**, Sommer J. Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group. **Ann Oncol**. 2017 Feb 9. [Epub ahead of print]
41. MacNeill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, **Casali PG**, Pollock RE, Raut CP, Gronchi A, Swallow CJ. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group. **Cancer**. 2017 Jun 1;123(11):1971-1978.
42. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altimari A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, **Casali PG**, Pinna AD, Astolfi A, Biasco G. Genome-wide Analyses Identifies MEN1 and MAX Mutations and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. **Mol Cancer Res**. 2017 Jan 27 [Epub ahead of print]
43. Andritsch E, Beishon M, Bielack S, Bonvalot S, **Casali P**, Crul M, Bolton RD, Donati DM, Douis H, Haas R, Hogendoorn P, Kozhaeva O, Lavender V, Lovey J, Negrouk A, Pereira P, Roca P, de Lempdes GR, Saarto T, van Berck B, Vassal G, Wartenberg M, Yared W, Costa A, Naredi P. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. **Crit Rev Oncol Hematol**. 2017;110:94-105.
44. Demetri GD, Blay JY, **Casali PG**. Advances and controversies in the management of soft tissue sarcomas. **Future Oncol**. 2017;13(1s):3-11
45. Saponara M, Stacchiotti S, **Casali PG**, Gronchi A. (Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. **Eur J Cancer**. 2017;70:1-11.
46. Raspagliesi F, Maltese G, Bogani G, Fucà G, Lepori S, De Iaco P, Perrone M, Scambia G, Cormio G, Bogliolo S, Bergamini A, Bifulco G, **Casali PG**, Lorusso D. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study. **Gynecol Oncol**. 2016 Nov 4 [Epub ahead of print]
47. Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, **Casali PG**, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. **J Invest Dermatol**. 2016 Sep 5 [Epub ahead of print]
48. Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, **Casali PG**, Picci P. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. **Ann Oncol**. 2016 Oct 11 [Epub ahead of print]
49. Colia V, Provenzano S, Morosi C, Collini P, Renne SL, Dagrada PG, Sangalli C, Dei Tos AP, Marrari A, **Casali PG**, Stacchiotti S. Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review. **Clin Sarcoma Res**. 2016 Sep 1;6(1):16.
50. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, **Casali PG**, Gronchi A. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. **Surg Oncol**. 2016 Sep;25(3):125-31.
51. Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, **Casali PG**. Sirolimus in Advanced Epithelioid Hemangiioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. **Ann Surg Oncol**. 2016 Sep;23(9):2735-44.
52. Colia V, Provenzano S, Hindi N, **Casali PG**, Stacchiotti S. Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma. **Rep Pract Oncol Radiother**. 2016 Jul-Aug;21(4):361-9.
53. Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, **Casali PG**, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. **Mol Cancer Res**. 2016 Sep;14(9):820-9.
54. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Pechoux CL, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, **Casali PG**, Gronchi A. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. **Lancet Oncol**. 2016 Apr 5. [Epub ahead of print]



55. Radaelli S, Stacchiotti S, Ruggieri P, Donati D, **Casali PG**, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, Gronchi A, Picci P. Sacral Chordoma: Long-Term Outcome of A Large Series of Patients Surgically Treated At Two Reference Centers. **Spine** (Phila Pa 1976). 2016 Apr 6. [Epub ahead of print]
56. Raut CP, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Fiore M, Callegaro D, **Casali PG**, Haas RL, Hayes AJ, Honore C, Cannell AJ, Jakob J, Szacht M, Fairweather M, Pollock RE, Bonvalot S, Gronchi A. External validation of a multi-institutional retroperitoneal sarcoma nomogram. **Cancer**. 2016 May 1;122(9):1417-24. [Epub ahead of print]
57. Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, **Casali PG**, Pollock RE, Raut CP. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. **Ann Surg**. 2015 Dec 31. [Epub ahead of print]
58. Benjamin RS, **Casali PG**. Adjuvant Imatinib for GI Stromal Tumors: When and For How Long? **J Clin Oncol**. 2015 Dec 7. [Epub ahead of print]
59. Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, Stacchiotti S, **Casali PG**, Gronchi A. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. **Eur J Cancer**. 2015 Dec;51(18):2800-7.
60. **Casali PG**, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcborg JR, Litière S, Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. **J Clin Oncol**. 2015 Dec 20;33(36):4276-83.
61. Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, **Casali PG**, Gronchi A. Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. **J Clin Oncol**. 2015 Nov 1;33(31):3628-34.
62. Hindi N, **Casali PG**, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A, Stacchiotti S. Imatinib in advanced chordoma: A retrospective case series analysis. **Eur J Cancer**. 2015 Nov;51(17):2609-14.
63. Goldbraich E, Waks Z, Farkash A, Monti M, Torresani M, Bertulli R, **Casali PG**, Carmeli B. Understanding Deviations from Clinical Practice Guidelines in Adult Soft Tissue Sarcoma. **Stud Health Technol Inform**. 2015;216:280-4.
64. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, **Casali PG**. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). **Clin Cancer Res**. 2015 Aug 10. [Epub ahead of print]
65. Barrios CH, Blackstein ME, Blay JY, **Casali PG**, Chacon M, Gu J, Kang YK, Nishida T, Purkayastha D, Woodman RC, Reichardt P. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. **Eur J Cancer**. 2015 Nov;51(16):2423-33
66. Proserpio T, Ferrari A, Lo Vullo S, Massimino M, Clerici CA, Veneroni L, Bresciani C, **Casali PG**, Ferrari M, Bossi P, Galmozzi G, Pierantozzi A, Licitra L, Marcegaglia S, Mariani L. Hope in cancer patients: the relational domain as a crucial factor. **Tumori**. 2015 Jul-Aug;101(4):447-54.
67. Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, **Casali PG**, Caraceni A, Gronchi A, Fiore M. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. **Br J Surg**. 2015 Aug;102(9):1079-87.
68. **Casali PG**. Adjuvant chemotherapy for soft tissue sarcoma. **Am Soc Clin Oncol Educ Book**. 2015;35:e629-33.
69. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, Gronchi A, **Casali PG**, Maestro R, Dei Tos AP. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. **Am J Surg Pathol**. 2015 Jul;39(7):922-30
70. Sandrucci S, Gatta G, Trama A, Dei Tos AP, **Casali PG**. Specialized teams or specialist networks for rare cancers? **Eur J Surg Oncol**. 2015 Sep;41(9):1115-7.
71. Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, Colombo C, Crippa F, Morosi C, **Casali PG**, Pilotti S, Stacchiotti S, Rivoltini L, Castelli C. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. **BMC Cancer**. 2015;15:58.
72. Dittrich C, Negrouk A, **Casali PG**; European Society for Medical Oncology (ESMO) Switzerland, and the European Organisation for Research and Treatment of Cancer (EORTC), Belgium. An ESMO-EORTC position

- paper on the EU Clinical Trials Regulation and EMA's Transparency Policy: Making European research more competitive again. **Ann Oncol**. 2015 May;26(5):829-32.
73. Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, **Casali** PG, Maki RG, Cioffi A, Mearthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. **Eur J Cancer**. 2015 May;51(7):852-60.
  74. Provenzano S, Hindi N, Morosi C, Ghilardi M, Collini P, **Casali** PG, Stacchiotti S. Response of conventional chondrosarcoma to gemcitabine alone: a case report. **Clin Sarcoma Res**. 2015 Mar 15;5:9.
  75. Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, **Casali** PG. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. **Anticancer Drugs**. 2015 Jul;26(6):678-81.
  76. Blay JY, **Casali** PG, Dei Tos AP, Le Cesne A, Reichardt P. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. **Oncology**. 2015;89(1):1-13
  77. Stacchiotti S, Sommer J; **Chordoma Global Consensus Group**. Building a global consensus approach to chordoma: a position paper from the medical and patient community. **Lancet Oncol**. 2015 Feb;16(2):e71-83
  78. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, Gronchi A, **Casali** PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. **Clin Sarcoma Res**. 2014 Nov 22;4(1):16.
  79. Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, **Casali** PG, Dei Tos AP, Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. **Am J Surg Pathol**. 2015 Mar;39(3):383-93.
  80. Colombo C, Miceli R, Le Péchoux C, Palassini E, Honoré C, Stacchiotti S, Mir O, **Casali** PG, Dômont J, Fiore M, Le Cesne A, Gronchi A, Bonvalot S. Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. **Eur J Cancer**. 2015 Jan;51(2):186-92.
  81. Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, **Casali** PG, Picci P, Ferrari S, Aglietta M; for the Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. **Lancet Oncol**. 2015 Jan;16(1):98-107.
  82. Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti M, Picci P, Daolio PA, Parafioriti A, Morris C, Antonescu CR, Gronchi A, **Casali** PG, Donati DM, Ferrari S, Stacchiotti S. Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. **Eur J Cancer**. 2015 Jan;51(2):210-7.
  83. Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, **Casali** PG, Gronchi A, Fiore M. Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. **Eur J Surg Oncol**. 2014 Dec;40(12):1662-70.
  84. Gronchi A, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, **Casali** PG, Le Cesne A, Mariani L, Colombo C, Bonvalot S. Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. **Ann Surg Oncol**. 2015 May;22(5):1447-54.
  85. **Casali** PG, Bruzzi P, Bogaerts J, Blay JY; on behalf of the Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. **Ann Oncol**. 2015 Feb;26(2):300-306.
  86. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, **Casali** PG, Zaffaroni N. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. **Eur J Cancer**. 2014 Nov;50(17):3021-8.
  87. Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, Pantaleo MA, Fumagalli E, Venturoli N, Palassini E, Consolini N, **Casali** PG, Biasco G, Hrelia P. Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. **Eur J Hum Genet**. 2014 Sep 17.
  88. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2014 Sep;25 Suppl 3:iii21-6.
  89. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2014 Sep;25 Suppl 3:iii113-23.
  90. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2014 Sep;25 Suppl 3:iii102-12.
  91. De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, **Casali** PG, Canevari S, Pierotti MA, Pilotti S. Identification of a gene expression driven progression pathway in myxoid liposarcoma. **Oncotarget**. 2014 Aug 15;5(15):5965-77.
  92. Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, Gronchi A, Stacchiotti S, **Casali** PG, Pilotti S, Rivoltini L, Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. **Br J Cancer**. 2014 Sep 23;111(7):1350-62.

93. Bellera CA, Penel N, Ouali M, Bonvalot S, **Casali** PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. **Ann Oncol**. 2014 Jul 28.
94. **Casali** PG; European Society for Medical Oncology (ESMO) Switzerland. Risks of the new EU Data Protection Regulation: an ESMO position paper endorsed by the European oncology community. **Ann Oncol**. 2014 Aug;25(8):1458-61.
95. Ciardiello F, Arnold D, **Casali** PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, Popescu R, Van Cutsem E, Zielinski C, Stahel R. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). **Ann Oncol**. 2014 Sep;25(9):1673-8.
96. Milione M, Gasparini P, Sozzi G, Mazzaferro V, Ferrari A, **Casali** PG, Perrone F, Tamborini E, Pellegrinelli A, Gherardi G, Arrigoni G, Collini P, Testi A, De Paoli E, Aiello A, Pilotti S, Pelosi G. Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation. **Histopathology**. 2014 Jun;64(7):1014-26.
97. **Casali** PG. Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors. **Prog Tumor Res**. 2014;41:51-61.
98. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, **Casali** PG. Activity of sunitinib in extraskeletal myxoid chondrosarcoma. **Eur J Cancer**. 2014 Jun;50(9):1657-64.
99. **Casali** PG. Rare cancers: work in progress in Europe. **Ann Oncol**. 2014 Apr;25(4):914.
100. Radaelli S, Stacchiotti S, **Casali** PG, Gronchi A. Emerging therapies for adult soft tissue sarcoma. **Expert Rev Anticancer Ther**. 2014 Jun;14(6):689-704.
101. Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczky M, Cats A, **Casali** PG, Treckmann J, van Coevorden F, Gronchi A. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). **Eur J Surg Oncol**. 2014 Apr;40(4):412-9.
102. Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, **Casali** PG, Swallow CJ, Gronchi A, Bonvalot S, Raut CP. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. **Ann Surg**. 2014 May;259(5):973-8.
103. Stacchiotti S, Dagrada GP, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S, **Casali** PG. Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. **Clin Sarcoma Res**. 2013 Dec 18;3(1):16.
104. Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, Cervantes A, **Casali** PG, Sessa C, Van Cutsem E, de Vries E, Pavlidis N, Fumasoli K, Wörmann B, Samonigg H, Cascinu S, Cruz Hernández JJ, Howard AJ, Ciardiello F, Stahel RA, Piccart M. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). **Ann Oncol**. 2014 Jan;25(1):9-15.
105. Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, **Casali** PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm - a position paper from the Italian and the French Sarcoma Group. **Ann Oncol**. 2014 Mar;25(3):578-83.
106. European Partnership Action Against Cancer consensus group, Borrás JM, Albrecht T, Audisio R, Briers E, **Casali** P, Esperou H, Grube B, Hamoir M, Henning G, Kelly J, Knox S, Nabal M, Pierotti M, Lombardo C, van Harten W, Poston G, Prades J, Sant M, Travado L, Valentini V, van de Velde C, van den Bogaert S, van den Bulcke M, van Hoof E, van den Neucker I, Wilson R. Policy statement on multidisciplinary cancer care. **Eur J Cancer**. 2014 Feb;50(3):475-80.
107. Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarra P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P, **Casali** PG. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. **Eur J Cancer**. 2014 Mar;50(4):784-92.
108. Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, **Casali** PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D'Incalci M. Mode of action of trabectedin in myxoid liposarcomas. **Oncogene**. 2014 Oct 30;33(44):5201-10.
109. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, **Casali** PG, Fernandez-Serra A, Lopez-Pousa A, Gronchi A. MRP1 overexpression determines poor

- prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study. **Mol Cancer Ther.** 2014 Jan;13(1):249-59.
110. Stacchiotti S, Marrari A, Dei Tos AP, **Casali** PG. Targeted therapies in rare sarcomas: IMT, ASPS, SFT, PEComa, and CCS. **Hematol Oncol Clin North Am.** 2013 Oct;27(5):1049-61.
  111. Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, **Casali** PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. **Clin Cancer Res.** 2013 Sep 15;19(18):5192-201.
  112. Gronchi A, **Casali** PG. Adjuvant therapy for high-risk soft tissue sarcoma in the adult. **Curr Treat Options Oncol.** 2013 Sep;14(3):415-24.
  113. Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina E, Hoiczky M, Cats A, **Casali** PG, Le Cesne A, Treckmann J, Stoeckle E, de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C, van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. **Ann Surg Oncol.** 2013 Sep;20(9):2937-43.
  114. Duranti L, Gronchi A, Stacchiotti S, Fiore M, **Casali** PG, Collini P, Pelosi G, Galeone C, Pastorino U. Localised thoracic sarcomas: outcome improvement over time at a single institution. **Eur J Cancer.** 2013 Aug;49(12):2689-97.
  115. Sanfilippo R, Dei Tos AP, **Casali** PG. Myxoid liposarcoma and the mammalian target of rapamycin pathway. **Curr Opin Oncol.** 2013 Jul;25(4):379-83.
  116. Stacchiotti S, Crippa F, Messina A, Pilotti S, Gronchi A, Blay JY, **Casali** PG. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. **Clin Sarcoma Res.** 2013 May 13;3(1):8.
  117. Sanfilippo R, **Casali** PG. The intriguing patterns of tumor response to trabectedin. **Expert Rev Anticancer Ther.** 2013 Jun;13(6 Suppl 1):21-4.
  118. Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, **Casali** PG. Response to chemotherapy of solitary fibrous tumour: a retrospective study. **Eur J Cancer.** 2013 Jul;49(10):2376-83.
  119. Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, Stacchiotti S, Sangalli C, **Casali** PG, Gronchi A, Fiore M. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. **Ann Oncol.** 2013 Aug;24(8):2181-9.
  120. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, Gronchi A, Pilotti S, **Casali** PG. Phase II study on lapatinib in advanced EGFR-positive chordoma. **Ann Oncol.** 2013 Jul;24(7):1931-6.
  121. Baldi GG, Stacchiotti S, Mauro V, Dei Tos AP, Gronchi A, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S, **Casali** PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. **Clin Sarcoma Res.** 2013 Apr 3;3:4.
  122. **Casali** PG. Improving methodology to go beyond histology in rare cancers. **Lancet Oncol.** 2013 Apr;14(4):276-7.
  123. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Ubaldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, **Casali** PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Role of macrophage targeting in the antitumor activity of trabectedin. **Cancer Cell.** 2013 Feb 11;23(2):249-62.
  124. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, **Casali** PG; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. **Lancet.** 2013 Jan 26;381(9863):295-302.
  125. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2012 Oct;23 Suppl 7:vii92-9.
  126. ESMO / European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2012 Oct;23 Suppl 7:vii49-55.
  127. ESMO / European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol.** 2012 Oct;23 Suppl 7:vii100-9.
  128. Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M, **Casali** PG, Hrelia P, Cantelli-Forti G, Biasco G. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. **Pharmacol Res.** 2013 Feb;68(1):1-6.
  129. Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M, **Casali** PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. **Ann Oncol.** 2013 Mar;24(3):817-23.

130. Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, **Casali PG**; RARECARE Working Group. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. **Eur J Cancer**. 2013 Feb;49(3):684-95.
131. Stacchiotti S, Dagrada GP, Morosi C, Negri T, Romanini A, Pilotti S, Gronchi A, **Casali PG**. Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. **Clin Sarcoma Res**. 2012 Oct 11;2(1):22.
132. **Casali PG**. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. **Ann Oncol**. 2012 Sep;23 Suppl 10:x167-9.
133. Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, **Casali PG**, Decatris M, Eriksson M, Gelderblom H, Kosmidis P, Le Cesne A, Pousa AL, Schlemmer M, Verweij J, Joensuu H. Adjuvant therapy in primary GIST: state-of-the-art. **Ann Oncol**. 2012 Nov;23(11):2776-81.
134. Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, **Casali PG**, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. **Eur J Cancer**. 2012 Nov;48(16):3036-44.
135. **Casali PG**, Fumagalli E, Gronchi A. Adjuvant therapy of gastrointestinal stromal tumors (GIST). **Curr Treat Options Oncol**. 2012 Sep;13(3):277-84.
136. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, Morosi C, Messina A, Pilotti S, **Casali PG**. Sunitinib malate in solitary fibrous tumor (SFT). **Ann Oncol**. 2012 Dec;23(12):3171-9.
137. Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, **Casali PG**. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. **Clin Cancer Res**. 2012 Jun 1;18(11):3170-9.
138. **Casali PG**, Dei Tos AP. A new journal... on spindle cells. **Clin Sarcoma Res**. 2011 Jul 25;1(1):1.
139. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Lombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, **Casali PG**, Gronchi A. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. **Cancer**. 2012 Dec 1;118(23):5857-66.
140. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, **Casali PG**, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. **Lancet**. 2012 May 19;379(9829):1879-86.
141. Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, Stacchiotti S, Fiore M, Mariani L, **Casali PG**, Gronchi A. Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or 2 faces of the same disease? **Cancer**. 2012 Nov 1;118(21):5349-57.
142. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, **Casali PG**. Phase II study of imatinib in advanced chordoma. **J Clin Oncol**. 2012 Mar 20;30(9):914-20.
143. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, **Casali PG**, Picci P. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. **J Clin Oncol**. 2012 Mar 10;30(8):850-6.
144. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, Gronchi A, Dusio GF, Pelosi G, Picci P, **Casali PG**, Pierotti MA, Pilotti S. Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. **Genes Chromosomes Cancer**. 2012 Feb;51(2):111-26.
145. Gatta G, van der Zwan JM, **Casali PG**, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. **Eur J Cancer**. 2011 Nov;47(17):2493-511.
146. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, Gronchi A, **Casali PG**, Dei Tos AP. Natural history of imatinib-naïve GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. **Am J Surg Pathol**. 2011 Nov;35(11):1646-56.
147. **Casali PG**, Sanfilippo R. Uterine sarcomas: a multidisciplinary challenge. **Eur J Cancer**. 2011 Sep;47 Suppl 3:S326-7.
148. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, **Casali PG**. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. **Gynecol Oncol**. 2011 Dec;123(3):553-6.
149. Fiore M, Colombo C, Locati P, Berselli M, Radaelli S, Morosi C, **Casali PG**, Gronchi A. Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. **Ann Surg Oncol**. 2012 Feb;19(2):511-8.

150. Gronchi A, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M, **Casali** PG. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. **Ann Oncol**. 2012 Apr;23(4):1067-73.
151. **Casali** PG. Medical oncology: the long-awaited prize of recognition. **Ann Oncol**. 2011 Aug;22(8):1695-7.
152. Stacchiotti S, **Casali** PG. Systemic therapy options for unresectable and metastatic chordomas. **Curr Oncol Rep**. 2011 Aug;13(4):323-30.
153. Joensuu H, De Braud F, Grignani G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, **Casali** PG. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. **Br J Cancer**. 2011 May 24;104(11):1686-90.
154. Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. **Ann Oncol**. 2012 Feb;23(2):508-16.
155. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, **Casali** PG. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. **Ann Oncol**. 2012 Feb;23(2):501-8.
156. Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, Gronchi A, **Casali** PG, Pierotti MA, Tamborini E, Pilotti S. Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFR $\alpha$  and Bcl-2 expression in gastrointestinal stromal tumors. **Anal Quant Cytol Histol**. 2010 Aug;32(4):225-33.
157. Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilippo R, **Casali** PG, Le Cesne A, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. **Eur J Cancer**. 2011 May;47(7):1006-12.
158. Italiano A, Laurant A, Laroche A, **Casali** P, Sanfilippo R, Le Cesne A, Judson I, Blay JY, Ray-Coquard I, Bui B, Coindre JM, Nieto A, Tercero JC, Jimeno J, Robert J, Pourquier P. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. **Cancer**. 2011 Aug 1;117(15):3445-56.
159. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, **Casali** PG, Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. **Ann Oncol**. 2011 Jul;22(7):1682-90.
160. Gronchi A, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M, **Casali** PG. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. **Ann Oncol**. 2011 Jul;22(7):1675-81.
161. Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S, **Casali** PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. **Int J Cancer**. 2011 Oct 1;129(7):1761-72.
162. Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, **Casali** PG, Ferrari S, Aglietta M. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor- $\alpha$  or - $\beta$ : An Italian Sarcoma Group study. **Cancer**. 2011 Feb 15;117(4):826-31.
163. Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, **Casali** PG, Gronchi A. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. **Ann Surg Oncol**. 2011 Mar;18(3):720-5.
164. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, Sartor C, Barbareschi M, Cantaloni C, Messerini L, Bearzi I, Arrigoni G, Mazzoleni G, Fletcher JA, **Casali** PG, Talamini R, Maestro R, Dei Tos AP. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. **Am J Surg Pathol**. 2010 Oct;34(10):1480-91.
165. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, **Casali** PG, Gronchi A. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. **Ann Surg Oncol**. 2010 Dec;17(12):3229-33.
166. **Casali** PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2010 May;21 Suppl 5:v98-102.
167. **Casali** PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2010 May;21 Suppl 5:v198-203.
168. **Casali** PG. Do rare cancers deserve specific strategies for cancer research? **Lancet Oncol**. 2010 Jun;11(6):506-7.
169. **Casali** PG, Sanfilippo R, D'Incalci M. Trabectedin therapy for sarcomas. **Curr Opin Oncol**. 2010 Jul;22(4):342-6.
170. Dileo P, Pricl S, Tamborini E, Negri T, Stacchiotti S, Gronchi A, Posocco P, Laurini E, Coco P, Fumagalli E, **Casali** PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized

- PDGFRA mutations: an imaging, biochemical and molecular modeling study. **Int J Cancer**. 2011 Feb 15;128(4):983-90.
171. Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, **Casali PG**, Pilotti S. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. **Mol Cancer Ther**. 2010 May;9(5):1286-97.
  172. Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaiene H, Le Péchoux C, **Casali PG**, Le Cesne A, Fiore M, Gronchi A. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. **Ann Surg Oncol**. 2010 Jun;17(6):1507-14.
  173. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, **Casali PG**, Gronchi A, Viridis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. **Cancer Res**. 2010 Mar 15;70(6):2235-44.
  174. Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, **Casali PG**, Gronchi A. Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. **Cancer**. 2010 May 15;116(10):2429-36.
  175. Tamborini E, Viridis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, **Casali PG**, Pierotti MA, Pilotti S. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. **Neuro Oncol**. 2010 Aug;12(8):776-89.
  176. Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, **Casali PG**. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. **Ann Surg**. 2010 Mar;251(3):506-11.
  177. Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, **Casali PG**. Tumor response to sunitinib malate observed in clear-cell sarcoma. **Ann Oncol**. 2010 May;21(5):1130-1.
  178. Stacchiotti S, **Casali PG**, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, Gronchi A, Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. **Ann Surg Oncol**. 2010 Jan;17(1):211-9.
  179. Demetri GD, **Casali PG**, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. **Clin Cancer Res**. 2009 Sep 15;15(18):5910-6.
  180. Mertens F, Antonescu CR, Hohenberger P, Ladanyi M, Modena P, D'Incalci M, **Casali PG**, Aglietta M, Alvegård T. Translocation-related sarcomas. **Semin Oncol**. 2009 Aug;36(4):312-23.
  181. Mussi C, Ronellenfitch U, Jakob J, Tamborini E, Reichardt P, **Casali PG**, Fiore M, Hohenberger P, Gronchi A. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? **Ann Oncol**. 2010 Feb;21(2):403-8.
  182. Le Cesne A, Van Glabbeke M, Verweij J, **Casali PG**, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciort R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. **J Clin Oncol**. 2009 Aug 20;27(24):3969-74.
  183. **Casali PG**, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:64-7.
  184. Paulussen M, Bielack S, Jürgens H, **Casali PG**; ESMO Guidelines Working Group. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:140-2.
  185. Bielack S, Carrle D, **Casali PG**; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:137-9.
  186. **Casali PG**, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2009 May;20 Suppl 4:132-6.
  187. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, Morosi C, Gronchi A, Pilotti S, **Casali PG**. Response to imatinib plus sirolimus in advanced chordoma. **Ann Oncol**. 2009 Nov;20(11):1886-94.
  188. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, **Casali PG**, Le Cesne A, Gronchi A, Bonvalot S. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. **Ann Surg Oncol**. 2009 Sep;16(9):2587-93.
  189. Grosso F, Sanfilippo R, Viridis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, **Casali PG**. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. **Ann Oncol**. 2009 Aug;20(8):1439-44.
  190. Gronchi A, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, **Casali PG**, Cesne AL, Hohenberger P, Blay JY. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies

- Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). **Eur J Cancer**. 2009 May;45(7):1103-6.
191. George S, Blay JY, **Casali** PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. **Eur J Cancer**. 2009 Jul;45(11):1959-68.
  192. Gronchi A, Bonvalot S, Le Cesne A, **Casali** PG. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. **J Clin Oncol**. 2009 Apr 20;27(12):2106-7; author reply 2107-8.
  193. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, Gronchi A, **Casali** PG. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. **Radiology**. 2009 May;251(2):447-56.
  194. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, **Casali** P, D'Incalci M, Pilotti S, Mantovani R. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. **Mol Cancer Ther**. 2009 Feb;8(2):449-57.
  195. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, **Casali** PG, Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma. **Clin Cancer Res**. 2009 Feb 1;15(3):1096-104.
  196. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, **Casali** PG, Gronchi A. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). **Eur J Surg Oncol**. 2009 Jul;35(7):739-45.
  197. Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L, **Casali** PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. **J Clin Oncol**. 2009 Jan 1;27(1):24-30.
  198. Miselli F, Negri T, Gronchi A, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, **Casali** PG, Pierotti MA, Tamborini E, Pilotti S. Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? **Transl Oncol**. 2008 Dec;1(4):177-86.
  199. Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, **Casali** PG, Gronchi A. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. **Cancer**. 2008 Oct 1;113(7):1657-65.
  200. **Casali** PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2008 May;19 Suppl 2:ii89-93.
  201. **Casali** PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. **Ann Oncol**. 2008 May;19 Suppl 2:ii35-8.
  202. **Casali** PG; Executive Committee of ESMO. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). **Ann Oncol**. 2007 Dec;18(12):1923-5.
  203. Gronchi A, Olmi P, **Casali** PG. Combined modalities approach for localized adult extremity soft-tissue sarcoma. **Expert Rev Anticancer Ther**. 2007 Aug;7(8):1135-44.
  204. Baratti D, Pennacchioli E, **Casali** PG, Bertulli R, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M, Gronchi A. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. **Ann Surg Oncol**. 2007 Dec;14(12):3542-51.
  205. Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent D, **Casali** PG. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. **Ann Oncol**. 2008 Jan;19(1):173-7.
  206. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, **Casali** PG, Beck-Peccoz P, Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. **J Clin Endocrinol Metab**. 2007 Sep;92(9):3531-4.
  207. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, **Casali** PG. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. **Lancet Oncol**. 2007 Jul;8(7):595-602.
  208. **Casali** PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. **Curr Opin Oncol**. 2007 Jul;19(4):367-70.
  209. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, **Casali** PG, Gronchi A. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. **Cancer**. 2007 Jun 15;109(12):2522-31.
  210. Orlandi E, Zonca G, Pignoli E, Stucchi C, Borroni M, Collini P, Cantù G, **Casali** PG, Grosso F, Cerrotta A, Fallai C, Olmi P. Postoperative radiotherapy for synovial sarcoma of the head and neck during pregnancy: clinical and technical management and fetal dose estimates. **Tumori**. 2007 Jan-Feb;93(1):45-52.
  211. Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, **Casali** PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S. c-Kit/PDGFRα gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. **Clin Cancer Res**. 2007 Apr 15;13(8):2369-77.



212. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, **Casali** PG. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. **Ann Surg**. 2007 Mar;245(3):341-6.
213. Verweij J, **Casali** PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, Issels R, van Oosterom AT, Van Glabbeke M, Blay JY. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. **Eur J Cancer**. 2007 Apr;43(6):974-8.
214. Gronchi A, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L, **Casali** PG. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. **Ann Surg Oncol**. 2007 May;14(5):1583-90.
215. Negri T, Casieri P, Miselli F, Orsenigo M, Piacenza C, Stacchiotti S, Bidoli P, **Casali** PG, Pierotti MA, Tamborini E, Pilotti S. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. **Br J Cancer**. 2007 Jan 15;96(1):180-1.
216. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, **Casali** PG, Pilotti S. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. **Clin Cancer Res**. 2006 Dec 1;12(23):6920-8.
217. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, **Casali** PG, Santinami M, Gronchi A. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. **Ann Surg Oncol**. 2007 Feb;14(2):553-9.
218. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, **Casali** PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. **Lancet**. 2006 Oct 14;368(9544):1329-38.
219. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, **Casali** PG, Pilotti S, Gronchi A. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. **Cancer**. 2006 Sep 1;107(5):1065-74.
220. Van Glabbeke M, Verweij J, **Casali** PG, Simes J, Le Cesne A, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). **Eur J Cancer**. 2006 Sep;42(14):2277-85.
221. Tamborini E, Pricl S, Negri T, Lagonigro MS, Miselli F, Greco A, Gronchi A, **Casali** PG, Ferrone M, Fermeiglia M, Carbone A, Pierotti MA, Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. **Oncogene**. 2006 Oct 5;25(45):6140-6.
222. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, **Casali** PG. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. **Eur J Cancer**. 2006 Jul;42(10):1484-90.
223. Debiec-Rychter M, Sciort R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, **Casali** PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeyer A, Judson I; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. **Eur J Cancer**. 2006 May;42(8):1093-103.
224. Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, **Casali** PG, Carbone A, Pierotti MA, Pilotti S. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. **J Pathol**. 2006 Apr;208(5):615-23.
225. Fiore M, **Casali** PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C, Gronchi A. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. **Ann Surg Oncol**. 2006 Jan;13(1):110-7.
226. Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, **Casali** PG, Gronchi A. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. **J Clin Oncol**. 2005 Oct 20;23(30):7669-75.
227. Nonaka D, Kusamura S, Baratti D, **Casali** P, Cabras AD, Younan R, Rosai J, Deraco M. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. **Cancer**. 2005 Nov 15;104(10):2181-8.
228. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, **Casali** P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. **Endocr Relat Cancer**. 2005 Sep;12(3):657-66.
229. Van Glabbeke M, Verweij J, **Casali** PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciort R, Hogendoorn PC, Brown M, Bertulli R, Judson IR. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. **J Clin Oncol**. 2005 Aug 20;23(24):5795-804.
230. Zalcberg JR, Verweij J, **Casali** PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR; EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian

- Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. **Eur J Cancer**. 2005 Aug;41(12):1751-7.
231. **Casali PG, Picci P.** Adjuvant chemotherapy for soft tissue sarcoma. **Curr Opin Oncol**. 2005 Jul;17(4):361-5.
  232. Blay JY, Bonvalot S, **Casali P**, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD; GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. **Ann Oncol**. 2005 Apr;16(4):566-78. Erratum in: *Ann Oncol*. 2005 Jun;16(6):993.
  233. Diment J, Tamborini E, **Casali P**, Gronchi A, Carney JA, Colecchia M. Carney triad: case report and molecular analysis of gastric tumor. **Hum Pathol**. 2005 Jan;36(1):112-6.
  234. **Casali PG, Bertulli R, Fumagalli E, Coco P, Grosso F, Stacchiotti S.** Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors. **J Chemother**. 2004 Nov;16 Suppl 4:55-8.
  235. Kusamura S, Raspagliesi F, Baratti D, Gronchi A, **Casali P**, Deraco M. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study. **J Chemother**. 2004 Nov;16 Suppl 5:19-22.
  236. Gronchi A, **Casali PG**, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P, Rosai J. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. **J Clin Oncol**. 2005 Jan 1;23(1):96-104.
  237. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, **Casali PG**, Gronchi A. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. **Cancer**. 2005 Jan 15;103(2):402-8.
  238. Verweij J, **Casali PG**, Zalcborg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. **Lancet**. 2004 Sep 25-Oct 1;364(9440):1127-34.
  239. **Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S.** Imatinib mesylate in chordoma. **Cancer**. 2004 Nov 1;101(9):2086-97.
  240. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, **Casali PG**. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. **Cancer**. 2004 Aug 1;101(3):627-34.
  241. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, **Casali PG**, Pierotti MA, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. **Gastroenterology**. 2004 Jul;127(1):294-9.
  242. Gronchi A, **Casali PG**, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M, Rosai J. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. **Cancer**. 2004 Jun 1;100(11):2448-55.
  243. Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, **Casali PG**, Pierotti MA, Pilotti S. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. **Clin Cancer Res**. 2004 Feb 1;10(3):938-43.
  244. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarra P, Collini P, Gronchi A, Olmi P, Fossati-Bellani F, **Casali PG**. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. **Cancer**. 2003 Aug 1;98(3):571-80.
  245. Deraco M, **Casali P**, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, Kusamura S. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. **J Surg Oncol**. 2003 Jul;83(3):147-53.
  246. Gronchi A, **Casali PG**, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. **J Clin Oncol**. 2003 Apr 1;21(7):1390-7.
  247. de Pas T, **Casali PG**, Toma S, Romanini A, Massidda B, Comandone A, Labianca R, Massacesi C, Tucci A, Antimi M, Biasco G, Aglietta M, Apice G, de Braud F; Italian Sarcoma Group. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? **Oncology**. 2003;64(2):186-8.
  248. Mezzelani A, Mariani L, Tamborini E, Agus V, Riva C, Lo Vullo S, Fabbri A, Stumbo M, Azzarelli A, **Casali PG**, Gronchi A, Sozzi G, Pierotti MA, Pilotti S. SYT-SSX fusion genes and prognosis in synovial sarcoma. **Br J Cancer**. 2001 Nov 16;85(10):1535-9.
  249. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, Dileo P, Rasponi A, Ferrari A, Pilotti S, **Casali PG**. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. **Cancer**. 2001 Sep 1;92(5):1259-64.
  250. Collini P, Sampietro G, Bertulli R, **Casali PG**, Luksch R, Mezzelani A, Sozzi G, Pilotti S. Cytokeratin immunoreactivity in 41 cases of ES/PNET confirmed by molecular diagnostic studies. **Am J Surg Pathol**. 2001 Feb;25(2):273-4.

251. **Casali** PG, Licitra L, Bruzzi P. QUOROM and the search for an updated 'clinical method' in the era of evidence-based medicine. **Ann Oncol**. 2000 Aug;11(8):923-5.
252. Costantini M, Mencaglia E, Giulio PD, Cortesi E, Roila F, Ballatori E, Tamburini M, **Casali** P, Licitra L, Candis DD, Massidda B, Luzzani M, Campora E, Placido SD, Palmeri S, Angela PM, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L. Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). **Qual Life Res**. 2000 Mar;9(2):151-9.
253. Mancuso T, Mezzelani A, Riva C, Fabbri A, Dal Bo L, Sampietro G, Perego P, **Casali** P, Zunino F, Sozzi G, Pierotti MA, Pilotti S. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. **Lab Invest**. 2000 Jun;80(6):805-13.
254. Tamburini M, **Casali** PG, Miccinesi G. Outcome assessment in cancer management. **Surg Clin North Am**. 2000 Apr;80(2):471-86, viii.
255. Frustaci S, Buonadonna A, Romanini A, Comandone A, Dalla Palma M, Gamucci T, Verusio C, Lionetto R, Dani C, **Casali** P, Santoro A. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. **Tumori**. 1999 Jul-Aug;85(4):229-33.
256. **Casali** P, Licitra L, Tondini C, de Braud F, Bruzzi P, Costa A, Cavalli F. START: a European state-of-the-art on-line instrument for clinical oncologists. **Ann Oncol**. 1999 Jul;10(7):769-73.
257. **Casali** P, Licitra L, Costantini M, Santoro A, Viterbori P, Bajetta E, Bruzzi P. Quality of life assessment and clinical decision-making. **Ann Oncol**. 1997 Dec;8(12):1207-11.
258. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, **Casali** P, Spooner D, Rankin E, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. **J Clin Oncol**. 1995 Jul;13(7):1537-45.
259. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, **Casali** P, Demicheli R, Valagussa P. Drugs ten years later: epirubicin. **Ann Oncol**. 1993 May;4(5):359-69.
260. **Casali** P, Pastorino U, Azzarelli A, Bertulli R, Zucchinelli P, Devizzi L, Santoro A. Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. **Cancer Chemother Pharmacol**. 1993;31 Suppl 2:S228-32.
261. Azzarelli A, Quagliuolo V, **Casali** P, Fissi S, Montalto F, Santoro A. Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. **Cancer Chemother Pharmacol**. 1993;31 Suppl 2:S210-2.
262. Azzarelli A, Quagliuolo V, Fissi S, **Casali** P, Garbuglia A, Bignami P, Santoro A, Andreola S, Gennari L. Intra-arterial induction chemotherapy for soft tissue sarcomas. **Ann Oncol**. 1992 Apr;3 Suppl 2:S67-70.
263. **Casali** P, Pastorino U, Zucchinelli P, Devizzi L, Azzarelli A, Quagliuolo V, Bignami P, Santoro A, Bonadonna G. Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas. **Ann Oncol**. 1992 Apr;3 Suppl 2:S125-6.
264. Bidoli P, Spinazzè S, Santoro A, **Casali** P, Bedini AV, Guzzon A. Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma. **Am J Clin Oncol**. 1990 Oct;13(5):424-6.
265. Pastorino U, Valente M, Santoro A, Gasparini M, Azzarelli A, **Casali** P, Tavecchio L, Rayasi G. Results of salvage surgery for metastatic sarcomas. **Ann Oncol**. 1990 Jul;1(4):269-73.
266. Gianni L, Viganò L, Surbone A, Ballinari D, **Casali** P, Tarella C, Collins JM, Bonadonna G. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. **J Natl Cancer Inst**. 1990 Mar 21;82(6):469-77.
267. Pastorino U, Valente M, Gasparini M, Azzarelli A, Santoro A, Tavecchio L, **Casali** P, Ravasi G. Median sternotomy and multiple lung resections for metastatic sarcomas. **Eur J Cardiothorac Surg**. 1990;4(9):477-81.

## Annex 2

### Selected list of **Book chapters, in English**

1. **Casali PG**, Dei Tos AP, Gronchi A. Gastrointestinal stromal tumor. In: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology* (DeVita VT, Lawrence TS, Rosenberg SA, eds), 11th edition, Philadelphia: Wolters Kluwer, 2019, pp. 895-907
2. Gronchi A, Dei Tos AP, **Casali PG**. Sarcomas of soft tissues and bone. In: *Oxford Textbook of Oncology* (Kerr DJ, Haller DG, van de Velde CJH, Baumann M, eds), 3<sup>rd</sup> edition, Oxford: Oxford University Press, 2016, pp. 844-866
3. **Casali PG**, Dei Tos AP, Gronchi A. Gastrointestinal stromal tumor. In: *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology* (DeVita VT, Lawrence TS, Rosenberg SA, eds), 10th edition, Philadelphia: Wolters Kluwer, 2014, pp. 745-756
4. **Casali PG**, Picci P. Sarcomas. In: *Textbook of Medical Oncology* (Cavalli F, Hansen HH, Kaye SB, eds.), 3<sup>rd</sup> Ed., London & New York: Taylor & Francis, 2004, pp. 235-248
5. Santoro A, **Casali P**. Sarcomas. In: *Textbook of Medical Oncology* (Cavalli F, Hansen HH, Kaye SB, eds.), 1<sup>st</sup> Ed., London: Dunitz, 1997, pp. 217-228
6. **Casali P**, Santoro A. Bone malignant tumours other than osteosarcoma and Ewing's sarcoma. In: *Oxford Textbook of Oncology* (Peckam M, Pinedo HM, Veronesi U), 1<sup>st</sup> edition, Oxford: Oxford University Press, 1995, pp. 1976-1982
7. Santoro A, **Casali P**, Zucchinelli P. Ewing's sarcoma. In: *Handbook of Chemotherapy in Clinical Oncology* (Cvitkovic, Droz, Armand, Khoury), Scientific Communication International Ltd, 1993, pp. 680-682

### **Annex 3**

#### Selected list of **Books, in Italian**

- Bellani ML, Morasso G, Amadori D, Orrù W, Grassi L, **Casali PG**, Bruzzi P (a cura di). **Psiconcologia**. Milano, Masson; 2002
- **Casali P**, Licitra L, Santoro A. **Metodologia Clinica in Oncologia**. Napoli, Società Editrice Scientifica; 1991